BioSig Technologies (NASDAQ:BSGM) Given New $2.50 Price Target at Ascendiant Capital Markets

Posted by Lauren Steadman on Apr 21st, 2025

BioSig Technologies (NASDAQ:BSGM – Get Free Report) had its price target lowered by equities research analysts at Ascendiant Capital Markets from $2.75 to $2.50 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price indicates a potential upside of 320.17% from the stock’s previous close.

BioSig Technologies Stock Up 2.6 %

NASDAQ:BSGM opened at $0.60 on Monday. BioSig Technologies has a 1 year low of $0.20 and a 1 year high of $2.57. The stock’s 50 day simple moving average is $0.71 and its two-hundred day simple moving average is $1.06.

Hedge Funds Weigh In On BioSig Technologies

Institutional investors have recently bought and sold shares of the business. Legacy Investment Solutions LLC purchased a new position in BioSig Technologies in the fourth quarter worth about $5,369,000. Millennium Management LLC purchased a new position in shares of BioSig Technologies in the 4th quarter worth approximately $228,000. PFG Investments LLC bought a new position in shares of BioSig Technologies during the 4th quarter valued at approximately $164,000. Geode Capital Management LLC purchased a new stake in BioSig Technologies during the 4th quarter valued at $143,000. Finally, Integrity Wealth Advisors Inc. purchased a new position in BioSig Technologies during the fourth quarter worth $61,000. Institutional investors own 7.16% of the company’s stock.

BioSig Technologies Company Profile

(Get Free Report)

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.